ore than 1 million patients annually are at risk of brain ischemia and reperfusion injury that occurs secondary to life-saving endovascular or cardiac procedures.
In this study, we investigate the receptor-mediated signaling cascade required for poly-IClC-induced neuroprotection against ischemic brain injury using TlR3 −/− , MDA5 −/− , and IFN-promoter stimulator (IPS)-1 −/− mice. In addition, using IFN-β-deficient mice, we show that IFN-β is not involved in neuroprotection, and that exogenous administration of IFN-α protects against stroke, supporting a role for IFN-α in mediating poly-IClC-induced protection. −/− animals provided by Dr Edith Janssen (University of Cincinnati, Cincinnati, OH). IFN-β −/− mice provided by Dr Tomas leanderson (lund University). Studies were performed with male mice between 8 and 14 weeks of age. Mice were given free access to food and water and housed in a facility approved by the Association for Assessment and Accreditation of laboratory Animal Care International. Animal protocols were approved by the Oregon Health and Science University Institutional Animal Care and Use Committee (OWlAW A3304-01) and met the guidelines set forth by the National Institutes of Health. 
Materials and Methods

Mice
Study Design and Blinding
Mouse Ischemia-Reperfusion Model
Focal cerebral ischemia was induced by 60-or 45-minute middle cerebral artery occlusion (MCAO) as described previously. 4 Mice that did not show >80% reduction in cerebral blood flow, monitored with laser Doppler flowmetry (Transonic System Inc.), were excluded. Twenty-four hours after MCAO, infarct volume was measured as previously described. 4 
Cytokine Quantification
Plasma concentrations of IFN-α and IFN-β were determined using a Mouse IFN-α/IFN-β ProcartaPlex Multiplex Immunoassay (Affymetrix eBioscience) according to manufacturer instructions. Cytokine concentrations were extrapolated from the standard curve with samples below the standard curve assigned a value half that of the lowest standard.
Statistical Analysis
Data are represented as group mean±SEM and statistical analysis performed using GraphPad Prism6 software. Two-way ANOVA with Bonferroni post hoc test was used for infarct analysis and IFN-α/ IFN-β measurements.
Results
Poly-ICLC Requires MDA5, but Not TLR3, to Induce Neuroprotection
Potential cognate receptors for poly-IClC include TlR3, and the RIG-I-like receptor family members, RIG-I and MDA5 ( Figure 1A ). RIG-I and MDA5 recognize double-stranded RNA of different sizes, 5 thus we postulated that poly-IClC (≈500 kDa) would bind to MDA5, which recognizes larger double-stranded RNAs. 6 To determine whether TlR3 or , and MDA5 −/− mice were preconditioned with poly-IClC 24 hours before MCAO. As expected, poly-IClC preconditioning significantly reduced ischemic injury in WT animals (15.18±2.5% versus vehicle 32.57±1.8%; Figure 1B ). In addition, poly-IClC preconditioning significantly reduced ischemic injury in TlR3 −/− mice (4.81±2.1% versus vehicle 29.14±4.1%; Figure 1B ). No significant difference between poly-IClC-treated WT and TlR3 −/− mice was evident. In contrast, poly-IClC-treated MDA5 −/− mice failed to show a reduction in ischemic volume (29.63±3.1% versus vehicle 32.1±1.8%; Figure 1B ). These data indicate that poly-IClC preconditioning-induced neuroprotection is MDA5 dependent, demonstrating for the first time that a cytosolic receptor can mediate neuroprotection.
Poly-ICLC-Induced Neuroprotection Is Mediated Through IPS1
MDA5 signals through the adaptor molecule IFN-β-promoter stimulator (IPS1) leading to the induction of type I IFNs 5 ( Figure 1A ). Therefore, we tested the involvement of IPS1 in poly-IClC preconditioning using IPS1 −/− mice. IPS1 −/− mice preconditioned with poly-IClC failed to show a significant reduction in ischemic injury (40.8±2.5% versus vehicle 37.11±2.0%; Figure 1B ), demonstrating that poly-IClC preconditioning depends on both MDA5 and IPS1 for the induction of neuroprotection.
Poly-ICLC Induction of Type I IFNs Requires MDA5 and IPS1, Not TLR3
We have previously shown that poly-IClC requires type I IFN signaling for protection. 4 Therefore, we postulate that MDA5 and IPS1 mediate poly-IClC induction of IFN-α and/or IFN-β. We measured plasma IFN-α and IFN-β levels 6 hours after poly-IClC treatment in WT, TlR3 
IFN-β Is Not Required for Poly-ICLC Neuroprotection
IFN-β has been shown to provide protection against cerebral ischemic injury in experimental models of stroke, 7-9 thus we hypothesized that IFN-β may be the key mediator of neuroprotection. To test this, we preconditioned IFN-β −/− mice with poly-IClC 24 hours before ischemia. We found that IFN-β −/− mice were significantly protected against ischemic brain injury (poly-IClC, 21.54±5.3% versus vehicle, 41.91±5.8%; Figure 3A ), indicating that poly-IClC-induced neuroprotection is independent of IFN-β.
Systemic IFN-α Protects Against Stroke
The previous data indicate that IFN-β is not required, indicating that another type I IFN receptor ligand, such as IFN-α, may mediate the protective response. To test this, IFN-α was administered 18 hours before MCAO. This timing corresponds with the increase in serum levels of IFN-α induced by preconditioning with poly-IClC. We found that IFN-α-treated mice showed a significant reduction in ischemic volume (IFN-α, 18.11±4% versus vehicle, 33.19±5.1%; Figure 3B ), indicating that poly-IClC induction of systemic IFN-α may mediate protection against stroke.
Discussion
We demonstrate that poly-IClC preconditioning mediates neuroprotection through the cytoplasmic receptor MDA5 and its adapter IPS1. We have previously published that the type I IFN receptor is required for protection. 4 Here we show that, although systemic levels of both IFN-α and IFN-β are increased in response to poly-IClC preconditioning, the protective response is independent of IFN-βwhereas direct treatment with IFN-α protects the brain from ischemic injury, supporting a key role for IFN-α in poly-IClC neuroprotection. These findings broaden our knowledge of endogenous targets for the induction of neuroprotection against cerebral ischemic injury. In particular, the localization of these mediators of protection (both the receptor and its adapter molecule) in the cytoplasm may offer alternative drug delivery strategies for the translational development of therapeutic agents for stroke.
We found that neuroprotection induced by poly-IClC preconditioning is mediated exclusively through MDA5 and independent of TlR3. This is in contrast to a recent study using native poly-IC in which acute neuroprotection against brain ischemic injury was mediated through TlR3. 10 The apparent difference may relate to the chemical modification of polyIClC, which is a version of poly-IC that has been stabilized with poly-l-lysine and carboxymethylcellulose to improve pharmacokinetics. These alterations may influence the structure and trafficking of the compound resulting in different responses between poly-IClC and native poly-IC. Consistent with this postulate, we found that although poly-IClC was able to induce IFN-α and β in TlR3 −/− mice (Figure 2 ), poly-IC was unable to induce either IFN in the TlR3 −/− mice (data not shown). This difference is likely the result of altered trafficking of the 2 poly-IC compounds into the cell. This is supported by recent data by Dann et al 11 demonstrating that native (noncomplexed) poly-IC is a ligand for TlR3, whereas poly-IC in complex with polyethylenimine targets the cytoplasmic receptor MDA5. 12 Poly-IC complexation with polyethylenimine changes its cell delivery making it available for the cytosolic receptors. We propose that the lC component of poly-IClC modifies the cell delivery as well, making poly-IClC a specific ligand for cytosolic MDA5.
The association between stimulation of RIG-I-like receptors and reduction of central nervous system inflammation was previously reported by Dann et al, 11 who showed that activation of RIG-I and MDA5 reduced macrophage and lymphocyte infiltration into the spinal cord in an experimental model of multiple sclerosis. Similar to our results, this process was dependent on type I IFN receptor signaling. 4, 11 We and others have shown that prophylactic administration of TlR ligands induces neuroprotection against MCAO in mice. 13 Here, we demonstrate for the first time that the pattern recognition receptor, MDA5, is involved in neuroprotection. This may indicate the existence of a conserved feature shared among pattern recognition receptors for conferring protection against brain ischemic injury. This discovery has real significance in neuroprotection because it broadens substantially the possibilities of new approaches to achieve neuroprotection, particularly in the realm of preconditioning modalities.
Conclusions
Our results demonstrate that cytoplasmic receptors play an important role in preconditioning, and that MDA5 and its adapter IPS1 are required for poly-IClC-induced neuroprotection. These findings increase our understanding of the neuroprotective mechanisms associated with poly-IClC, furthering its development as a prophylactic treatment against ischemic injury. Furthermore, the results reported here expand our knowledge of potential endogenous targets for the development of new therapeutic agents for stroke.
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